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Disclaimer 
 
 
Certain commercial equipment, instruments, and materials are identified in 
this report to specify adequately the experimental procedure. In no case does such identification 
imply recommendation or endorsement by the European Commission, nor does it imply that the 
material or equipment is necessarily the best available for the purpose. 
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Abstract 
The production of ERM-DA471/IFCC, certified for the mass concentration of cystatin C, is 
described. 
Serum was produced from blood collected in 2 collection centres according to a procedure 
ensuring that it was obtained from healthy donors, and that the lipid content of the serum 
was low. The serum was processed, spiked with recombinant cystatin C, and lyophilised. It 
was verified that the material is homogenous and stable.  
The material was characterised using a pure protein primary reference preparation (PRP) as 
calibrant. The PRP was prepared from recombinant cystatin C, and its concentration 
determined by dry mass determination. The characterisation of ERM-DA471/IFCC was 
performed by particle enhanced immuno-nephelometry, particle enhanced immuno-
turbidimetry and enzyme amplified single radial immuno-diffusion.  
The certified cystatin C mass concentration in ERM-DA471/IFCC, if reconstituted according 
to the specified procedure, is 5.48 mg/L, the expanded uncertainty (k = 2) is 0.15 mg/L. 
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GLOSSARY 
ANOVA analysis of variance 
b slope in the equation of linear regression y = a + bx 
β slope of the linear regression y = βx 
Bit unit of the analog-to-digital converter of the light detector 
c mass concentration c = m / V (mass / volume) 
C3 complement 3 
C3c complement 3c 
CASO Casein Soy  
CRM Certified Reference Material 
CysC cystatin C 
ERM European Reference Material 
GFR glomerular filtration rate 
HBV hepatitis B virus 
HBsAg hepatitis B surface antigen 
HCV hepatitis C virus 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV human immunodeficiency virus 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
IRMM Institute for Reference Materials and Measurements 
IU International Units 
IVD In Vitro Diagnostic 
k coverage factor 
kDa kilo Dalton 
KIU Kallikrein Inhibitor Unit 
m mass 
MSbb mean sum of squares between bottles 
MSwb mean sum of squares within bottles 
N number of samples analysed 
n number of subsamples analysed 
PAGE polyacrylamide gel electrophoresis 
PRP primary reference preparation 
RF rheumatoid factor 
RSD relative standard deviation 
sbb standard deviation between bottles 
sbb, rel relative standard deviation between bottles 
SDS sodium dodecyl sulfate 
SRID single radial immuno-diffusion  
swb standard deviation within bottles 
SI International System of Units 
TM target material 
TRIS tris(hydroxymethyl)aminomethane 
U expanded uncertainty 
ubb, rel relative standard uncertainty related to the between-bottle heterogeneity 
u*bb, rel relative standard uncertainty related to the between-bottle heterogeneity that can 
be hidden by the method repeatability 
u*bb relative standard uncertainty related to the between-bottle heterogeneity that can 
be hidden by the method repeatability 
uc, rel relative combined standard uncertainty 
udm, cal, rel  relative standard uncertainty related to the characterisation of the calibrant 
upurity, cal, rel relative standard uncertainty related to the purity of the calibrant 
uchar, rel relative standard uncertainty related to the characterisation 
ults, rel relative standard uncertainty related to the long-term stability of the material 
usts, rel relative standard uncertainty related to the short-term stability of the material 
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1 Introduction and design of the project 
1.1 Background: Need for the CRM 
 
Cystatin C is a nonglycosylated, low molecular mass (13 kDa) protein produced by all 
nucleated cells. It is a protease inhibitor, and inhibits lysosomal cysteine proteases by 
binding reversibly to them. Its low molecular mass and its high isoeletric point allow it to be 
freely filtered by the renal glomerular membrane.  
The immunoassays routinely used for measuring the mass concentration of cystatin C give 
results that show a high between-method variation in External Quality Assessment 
Schemes. The availability of a validated international calibrator for cystatin C would allow 
elimination of the problems generated by the use of different cystatin C calibrators and non-
agreeing determination methods and thus promote the worldwide implementation of 
improved methods for non-invasive glomerular filtration rate (GFR) estimation, a measure of 
the capacity of the kidneys to filter plasma (GFR) [1, 2]. 
Plasma (or serum) cystatin C has been proposed as a marker for the GFR. Several studies 
(e.g. [3]), as well as one meta-analysis [4], have suggested that it is superior to serum 
creatinine for estimation of GFR. Particularly, cystatin C could be used for children, elderly, 
patients with low muscle mass, and in the early stages of kidney problems, where creatinine 
measurements do not perform well. Additionally cystatin C is used as a marker for 
cardiovascular  risk [5] and pre-eclampsia [6]. Knowledge of the GFR is of crucial importance 
in the management of patients. In addition to a general evaluation of the kidney function, a 
more accurate assessment is valuable on many occasions, e.g., to allow correct dosage of 
drugs cleared by the kidneys, to detect early impairment of renal function, to prevent further 
deterioration, to manage renal transplant patients, and for the use of potentially nephrotoxic 
radiographic contrast media. The determination of GFR with high accuracy requires the use 
of invasive techniques based on measuring the clearance of injected substances that are 
exclusively excreted via glomerular filtration, e.g., inulin, 51Cr- ethylenediaminetetraacetic 
acid, 99mTc-diethylenetriaminepentaacetic acid, or radiographic contrast media such as 125I-
iothalamate and iohexol. These procedures are labour-intensive and not free of risks for the 
patients. The plasma or serum concentrations of endogenous substances, particularly 
creatinine, have therefore been used as markers for GFR for more than a century. However, 
it has become evident that the creatinine concentration is far from ideal as a GFR marker 
because it is significantly influenced not only by GFR but also by factors such as muscle 
mass, diet, gender, age, race and tubular secretion [7-9].  
The level of cystatin C is less dependent upon anthropometric data than the level of 
creatinine and thus simpler cystatin C-based GFR prediction equations of the type GFR = 
A x cystatin C –B can be used [7-9]. It is nevertheless problematic that a large number of 
different cystatin C-based GFR-prediction equations have been proposed. The reasons for 
the variability of the suggested cystatin C-based GFR-prediction equations are the use of 
different cystatin C calibrators, the use of different, non-agreeing methods for determination 
of cystatin C levels, the use of different mathematical models to generate the prediction 
equations and the use of different patient populations. Although the large number of 
proposed cystatin C-based GFR-prediction equations is problematic per se in the 
implementation of cystatin C as a GFR-marker in the clinical routine, an even bigger problem 
is that it may generate large errors in the GFR estimates produced. For when a prediction 
equation, based upon a specific cystatin C calibrator and method, is used to estimate GFR 
from cystatin C levels produced using another cystatin C calibrator and method, large errors 
in the resulting GFR-estimates may result even for similar patient populations. 
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) 
requires the metrological traceability of calibrators and control materials through reference 
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measurement procedures and/or reference materials of higher order. The requirements for a 
calibrator for immunoassays are that the assignment of values is metrologically traceable, 
and is accompanied by an uncertainty statement, that the stability and homogeneity with 
respect to all the certified properties are verified, and that the material is commutable, i.e. 
resembles the patient samples [10].  
1.2 Choice of the material 
A material to be used to calibrate serum protein immunoassays has to be designed 
considering that: 
 the concentration of the protein in the final material should be high enough so  that 
dilutions of the material can cover a significant part of the measurement interval of 
the assays 
 the material should be optically clear. This property is important, as most clinical 
immunoassays use optical detection methods. 
The certification project first involved the characterisation of a primary reference preparation 
(PRP), consisting of liquid frozen recombinant cystatin C. Values were assigned to this 
preparation by dry mass determination [11]. 
Serum was produced from blood collected in collection centres in Lund (Sweden) and 
Marburg (Germany). 
The serum was processed, spiked with recombinant cystatin C and filled into vials (1 mL 
serum per vial) with screw caps. The serum was lyophilised in the vials and stored at (-70 ± 
10) °C. 
The material was characterised by transferring the values from the PRP to the candidate 
reference material (ERM-DA471/IFCC). This was achieved using a value transfer procedure 
that can be considered as a reference procedure [12].  
The principles used to measure the protein concentrations were enzyme amplified single 
radial immuno-diffusion (SRID), particle enhanced immuno-nephelometry and particle 
enhanced immuno-turbidimetry, as implemented on different measuring systems (BN IITM, 
and BN ProSpec®, Hitachi 917, Integra 800). In total 4 laboratories participated in the 
characterisation, and 7 datasets were used. 
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2 List of participants 
Provision and characterisation of cystatin C 
Dako Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
Department of Clinical Chemistry, University Hospital, Lund (SE)  
Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE)  
Siemens Healthcare Diagnostics Products GmbH, Marburg (DE) 
Provision and processing of the serum 
Siemens Healthcare Diagnostics Products GmbH, Marburg (DE) (certified ISO 13485 TÜV 
Rheinland Product Safety GmbH SX 60014517 0001)  
University Hospital MAS, Malmö (SE) (accred. ISO/IEC 17025:2005 SWEDAC) 
Stability and homogeneity studies 
Dako Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE) (accred. ISO Guide 34 BELAC 268-TEST) 
Characterisation 
Dako Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
Department of Clinical Chemistry, University Hospital, Lund (SE) (accred. ISO/IEC 17025 
SWEDAC 1424) 
Siemens Healthcare Diagnostics Products GmbH, Marburg (DE) (certified ISO 13485 TÜV 
Rheinland Product Safety GmbH SX 60014517 0001) 
Roche Diagnostics GmbH, Penzberg (DE) (certified ISO 13485 TÜV SÜD Q1N 07 08 45096 
003) 
Data analysis 
Department of Clinical Chemistry, University Hospital, Lund (SE) (accred. ISO/IEC 17025 
SWEDAC 1424) 
Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE) (accred. ISO Guide 34 BELAC 268-TEST) 
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3 Processing  
3.1 Materials 
3.1.1 Production of the serum  
The starting material for the reference material was serum prepared from the blood of 
healthy donors, collected in Lund, SE and Marburg, DE (Table 1). 
 
Selection of the donors: 
• Sex    both sexes 
• Age    20 – 70 years 
• Blood group   known 
• RF    < 30 IU/mL  
• Monoclonal components absent (checked by zone electrophoresis) 
• Bilirubin   serum colour visually normal 
• Hemoglobin   serum colour visually normal 
• Lipemia   no turbidity observed 
• Infectious agents  negative for: HBsAg, anti HIV 1, anti HIV 2 and  
anti HCV 
 
Serum collection protocol: 400 – 500 mL whole blood was withdrawn from each donor, 
expected to give an average serum volume of 180 mL (140 – 220 mL). 
 
The following protocol was applied for preparing the serum: 
 
a) Each whole blood sample was collected into a glass container that was suitable for 
centrifugation. 
b) Clotting: at least 5 hours at room temperature. 
c) First centrifugation at 1750 g for 35 minutes. 
d) After centrifugation the supernatant of the serum was transferred immediately to another 
container. 
e) Second centrifugation at 6850 g for 30 minutes. 
f) The supernatant of the serum was removed rapidly and the benzamidinium chloride 
brought to 1 mmol/L and NaN3 to 15 mmol/L. 
g) 5 aliquots of 0.5 mL were taken from each donor for testing. 
h) The serum was frozen immediately and stored individually at (-70 ± 10) °C until further 
processing, performed in 2006. 
 
Table 1: Summary information on the collected serum. The parenthetic numbers indicate how 
many male and female donations were fulfilling the inclusion criteria. 
Collection centre Donation period No. Male Female 
RF >30 
IU/mL 
Monoclonal 
components 
Age Final 
No. 
Malmö (SE) 02/2004 
to 
05/2005 
 
30 
 
26 (25) 
 
4 (4) 
 
0 
 
 
1 
 
20-64 
years 
 
29 
Marburg (DE) 09/2006 18 12 (11) 6 (4) 0 0 33-57 
years 
15 
 
Tests of the serum: The blood collection centres tested each donation for anti HIV 1+2, 
HBsAg, and anti HCV. Monoclonal gammopathies were detected by gel electrophoresis. 
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One donation was discarded because of the presence of monoclonal components, two 
donations were discarded because information on the blood group were not available and 
one donation was discarded because the donation was found to be slightly opalescent upon 
visual inspection. 44 donations, of which 8 originated from female donors, were fulfilling the 
inclusion criteria, and were released for further processing. 
 
3.1.2 Production of cystatin C and the Primary Reference Preparation 
Recombinant human cystatin C was produced by expression in E. Coli according to [13]. 
Cystatin C was purified from the cell extract using dialysis, anion- and cation exchange 
chromatography and gelfiltration. The purified cystatin C was filled into bottles and 
lyophilised. The lyophilised cystatin C was reconstituted using 0.1 mol/L KCl, dialysed 
against 0.1 mol/L KCl for 4 days with repeated replacements of the solvent and finally 
adjusted to a mass concentration of approximately 5.2 g/L as measured by refractometry. 
For use in the characterisation procedure the solution was aliquoted in vials of 0.2 mL and 
labelled Lot 11082006. 
5835 mg of a recombinant cystatin C solution (cystatin C spiking material Lot: 11082006-2; 
mass concentration about 5.2 g/L cystatin C (PRP) Dako Denmark, Glostrup (DK)) were 
used for spiking. The material was stored at (-70 ± 10) °C and thawed at 37 °C with 
occasional inversions. Before spiking the stabilised serum matrix, the cystatin C solution was 
gently mixed while avoiding any turbulence.  
 
3.2 Processing of the serum 
Overview of the procedure 
The serum donations from both collection centres were pooled and processed as one pool. 
The processing procedure followed largely the one used for CRM 470 (ERM-DA470) [14]. 
The major differences were that there was no conversion of C3 to C3c performed, that after 
the delipidation step a dialysis membrane with a cut-off of 10 kDa was used instead of 12-14 
kDa, and that the final sodium azide mass concentration was kept below 1 g/L. Particulate 
matter and lipids were removed and preservatives (sodium azide, aprotinin and benzamidine 
hydrochloride) were added. The stabilised serum matrix was spiked with recombinant 
cystatin C, sterile filtrated, filled into bottles and lyophilised. 
 
 
Figure 1: Overview of the processing of the serum.  
SE 
DE 
Thawing and 
pooling Delipidation Diaflitration 
Adtition of: 
HEPES, 
aprotinin, 
sodium azide, 
benzamidine 
hydrochloride 
Spiking with 
cystatin C 
    Sterile      
   filtration 
Filling, 
lyophilisation 
→ State B 
→ State A 
→ State C 
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3.2.1 Preparation of the stabilised serum matrix 
Donations fulfilling the criteria were processed as follows: 
• thawing at 25°C in a water bath  
• centrifugation at 11000 g  for 35 minutes  
• pooling of the supernatant of all accepted donations  
• removal of aliquots for the measurement of the concentrations of cholesterol, 
triglycerides, apolipoprotein A-I, apolipoprotein B and total protein (Biuret reaction).  
 
The material is now in state A. 
Delipidation with Aerosil 
• addition of sodium chloride (crystalline; Merck, Darmstadt, DE) to a final 
concentration of 50 g/L while stirring constantly 
• adjustment of the pool to pH 8.5 ± 0.1 with a saturated 
tris(hydroxymethyl)aminomethane (TRIS) solution (Merck, Darmstadt, DE) 
• calculation of the required amount of Aerosil 200 (Degussa, Frankfurt, DE) based on 
the total protein concentration of the pool (430 mg aerosil / g total protein) 
• gradual addition of Aerosil while stirring and constantly monitoring and if necessary 
adjusting the pH to 8.5 ± 0.1 
• continued slow stirring for another 60 minutes 
• removal of Aerosil (Degussa, DE) and protein precipitates by centrifugation for 30 
minutes at about 10000 g using 500 mL centrifugation bottles 
• determination of the total volume of the clear supernatant  
• determination of the concentrations of cholesterol, triglycerides and apolipoproteins 
A-I and B to verify the successful lipid removal. 
Filtration and diafiltration 
• filtration of the supernatant using a folded filter S&S Type 520½ (GE Healthcare 
Europe GmbH, Freiburg, DE) to remove small particles interfering with the following 
diafiltration  
• diafiltration (Centrasette with Omega membrane with a relative molecular mass cut-
off of 10000; Pall, Hauppauge, USA) using an isotonic sodium chloride solution to 
remove TRIS and Aerosil-derived free silica; this step combines buffer exchange and 
adjustment to the desired volume of the serum 
• removal of aliquots for the measurement of total protein and for the measurement 
and physicochemical analysis of selected proteins.  
 
The material is now in state B 
Preservation 
• addition of sodium azide (Merck, Darmstadt, DE) to achieve a final amount of 
substance concentration of 14.6 mmol/L (0.95 g/L) 
• addition of aprotinin (Trasylol 500000 KIU/L, Bayer, Leverkusen, DE) to achieve a 
final concentration of 80000 KIU/L 
• addition of benzamidine hydrochloride monohydrate (Merck, Darmstadt, DE) to a final 
amount of substance concentration of 1 mmol/L  
• adjustment of pH to 7.2 ± 0.1 with saturated 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (Calbiochem, Merck Biosciences, 
Schwalbach, DE) 
• removal of 200 mL for the preparation of the pilot batch PB001 
• preparation of 500 mL aliquots of the stabilised serum matrix; these aliquots were 
stored at (-70 ± 10) °C until processing to the final reference material. 
The material is now in state C.  
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Protein concentration measurements: Throughout the processing, the mass concentrations 
of cystatin C, apolipoprotein A-I and B were determined by immunonephelometry (double 
determinations) on a BN ProSpec or BN II System using reagents, standards and controls 
from Siemens.  
Total protein measurement: Determination of total protein was done according to the Biuret 
method using pure human serum albumin (internal Siemens Healthcare Diagnostics 
Products GmbH product) for calibration; solutions and chemicals were from Merck 
(Darmstadt, DE) or Sigma-Aldrich (Milwaukee, USA). 
Lipids: The cholesterol concentration was measured using the cholesterol CHOD-PAP Kit 
and triglycerides with the Triglycerides GPO Kit (Roche Diagnostics, Mannheim, DE). 
Blank signal: According to the specifications for the measuring system concerned an empty 
cuvette is considered adequately inserted and optically clear if the scattered light gives a 
signal between 20 and 600 Bit. 
3.2.2 Preparation of the candidate reference material 
• thawing and pooling of the aliquots of stabilised serum matrix (state C) at room 
temperature (24 hours) 
• preparation of the recombinant cystatin C as described under 3.1.2 
• slow addition of the total amount of the solution of recombinant cystatin C while 
constantly stirring 
• sterile filtration (0.2 µm) 
• sterile removal of aliquots for further analysis 
Filling was performed under controlled conditions. 1 mL serum was filled into uncoloured 
GW 2,5 threaded and siliconised glass bottles (ISO Gesellschaft für Arzneimittel mbH; Bad 
Königshofen, Germany), grey chlorobutylcaoutchouc GT rubber stoppers (West 
Pharmaceutical Services, Eschweiler, Germany) were used.  
A part of this material was not lyophilised, but left in liquid form and stored frozen at 
(-70 ± 10)°C. 
Within one hour after filling the lyophilisation program was started with cooling the serum to 
-40 °C over one hour. The vacuum equilibration was 10 to 30 Pa over 18 hours. Thereafter 
temperature was changed in successive steps to +25 °C over 22 hours. Capping of the 
bottles was performed under a low-pressure nitrogen atmosphere.  
Final capping was performed using yellow polypropylene screw caps, GL14 x 2.5 (Ki-Si-Co 
GmbH, Oestrich-Winkel, Germany)  The vials were finally labelled according to the filling 
order and stored frozen at (–70 ± 10) °C.   
3.2.3 Processing control 
Total protein mass concentration: In line with the protocol of the preparation of ERM-DA470 
a total protein mass concentration between 60 and 80 g/L is considered acceptable for the 
starting material for processing, and the Aerosil treated pool should be adjusted to between 
55 and 75 g/L. The total protein mass concentration of the pool was 78 g/L in state A and 64 
g/L in state C, within the defined tolerance limits. 
Delipidation: The delipidation by the Aerosil treatment is considered successful when the 
final mass concentrations of cholesterol and apolipoprotein B relative to the concentration in 
the starting material are reduced to below 1 %. The relative mass concentrations for 
triglycerides and apolipoprotein A-I should be below 15 % and 20 % of the starting material, 
respectively. As shown in Table 2, these criteria were fulfilled. The reduction of the blank 
value obtained by measuring the signal of undiluted sample using a BN100 System 
demonstrated the effective removal of lipoproteins. The Aerosil treatment also reduced the 
cystatin C concentration in the material (Table 3). 
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Table 2: Lipoproteins mass concentrations and blank signal measured with a nephelometer 
before processing (state A) and after Aerosil treatment (state B)1 
 
state A state B 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
Blank 
Value 
[Bit] 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
Blank 
Value 
[Bit] 
1969 1094 1550 857 846 ND ND ND ND 83 
 
1 when the concentration is below the limit of detection this is marked by ND (not detectable) 
 
 
 
Table 3: Cystatin C mass concentrations before and after Aerosil treatment 
 
cystatin C 
[mg/L] 
state A state B 
0.79 0.24 
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4 Homogeneity  
4.1 Homogeneity 
The homogeneity of ERM-DA471/IFCC was verified by measuring mass concentrations of 
cystatin C in triplicate in 20 vials taken randomly over the whole batch. The measurements 
were performed with a Hitachi 917 instrument and Dako reagents. The protein 
concentrations were corrected for deviations from the reconstitution protocol using the mass 
of the water used to reconstitute each sample. 
It was checked whether the data followed a normal or other unimodal distribution using 
normal probability plots and histograms. The individual data and the bottle means were 
unimodal, except for one outlying value.  
Grubbs tests were performed to detect outlying individual results as well as means 
measured for each vial. For one vial the mean was an outlier at the 95 % confidence level, 
but was retained in the analysis. There was no significant trend either in the analysis 
sequence or in the filling sequence.  
ANOVA statistics were used to calculate the between bottle standard deviation (sbb) and the 
maximum standard uncertainty related to the inhomogeneity that can be hidden by the 
method repeatability (u*bb), using the formulas: 
 
 
       
(MSbb = mean sum of squares between bottles; MSwb = mean sum of squares within bottles; 
n = number of replicates; dfwb = degrees of freedom within bottles) 
Both values were converted into relative uncertainties: sbb, rel = 0.294 %, and 
u*bb, rel = 0.151 %. The larger of both values was included into the calculation of the overall 
uncertainty of the certified values (Section 7.1). 
 
4.2 Minimum sample intake for analysis 
The reconstituted material forms a clear solution, and a true solution is not expected to have 
any relevant heterogeneity in protein concentration at sample intakes even below nL 
volumes. The sample intake of the homogeneity study on the material measured with a 
Hitachi 917 platform was 2 µL. The standard deviation within a bottle (swb) is lower or equal 
to the expected method variability (data not given), so there is no indication of intrinsic 
heterogeneity or contamination at a sample intake of 2 µL.  
n
MSMS
s wbbbbb
−
= 4
wb*
bb
2
wbdfn
MS
u ⋅=
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5 Stability 
Short- and long-term stability studies were carried out using an isochronous set-up [15] that 
consists of the simultaneous analysis of reference and test samples. For each study a 
defined set of samples was exposed to elevated temperatures for different periods of time 
and then brought back to the reference temperature. At the end of the study all samples 
were analysed for the concentrations of cystatin C within one analytical run. The data were 
analysed by determining the regression line for the protein concentration as a function of 
time [10]. 
5.1 Short-term stability 
A short-term stability study was performed in order to assess the possible effect of transport 
at different temperatures on the stability of the material. The reference temperature was 
below -140 °C, as the reference samples were stored above liquid nitrogen. Test samples 
were kept for 0, 1, 2, and 4 weeks at -20, 4, and 60 °C before being brought back to the 
reference temperature. For each combination of time and temperature 2 samples were 
analysed in triplicate. The samples were analysed for cystatin C using a Hitachi 917 
measuring system with Dako reagents. The values were corrected for the actual 
reconstitution volume. The results are shown in Table 4.  
Table 4: Short-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
relative standard uncertainty after two weeks storage at the specified temperature usts, rel 
temperature 
[°C] 
b 
[(mg/L)/week] |b/ub| 
usts, rel 
[%] 
-20 -0.018 3.66 0.39 
4 -0.003 0.38 0.26 
60 -0.022 5.50 0.46 
 
For each temperature there were 24 measurements, or 22 degrees of freedom for the linear 
regression. The slope of the protein concentration as a function of time is significantly 
different from 0 when the absolute value of slope b divided by its uncertainty ub (|b/ub|) is 
larger than t0.05, 22 = 2.07. When samples were kept at 4 °C the slope was not significantly 
different from 0. At -20 and 60 °C significant (at a 95 % confidence level) negative slopes 
were found although even at 60 °C the added uncertainty due to storage at this temperature 
for one week would be small. It was concluded from this study that the uncertainty due to 
degradation during dispatch is negligible if the material is shipped with cooling elements.  
5.2 Long-term stability 
The ERM-DA471/IFCC has been produced following the procedures for ERM-DA470 [14] 
very closely. One of the reasons for doing so is that ERM-DA470 has proven to be stable for 
all proteins for which values were certified in the material.  
6 months and 1 year stability studies were performed in order to confirm the stability of the 
new material upon storage at -20 and 4 °C. The reference temperature was (-70 ± 10) °C. 
The test samples were kept for 2, 4, and 6 months at -20 and 4 °C for the 6 months stability 
study, and for 4, 8, and 12 months for the 1 year stability study. For each combination of 
time and temperature 2 samples were analysed in triplicate. The samples were analysed for 
cystatin C using a Hitachi 917 measuring system with Dako reagents.  
For each temperature there were 24 measurements, or 22 degrees of freedom for the linear 
regression. The slope of the protein concentration as a function of time is significantly 
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different from 0 when the absolute value of slope b divided by its uncertainty ub (|b/ub|) is 
larger than t0.05, 22 = 2.07. None of the slopes (protein mass concentration versus time) was 
significantly different from 0 at a 95 % confidence level (Table 5). The uncertainty given for 
the long-term stability corresponds to the maximum uncertainty due to instability that could 
be hidden by the measurement variation after a period of 6 or 12 months. The results 
indicate that it is safe to store the material at either -20 or 4 °C. 
Table 5: Long-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
relative standard uncertainty contribution ults, rel after storage for 6 months or 1 year at the 
specified temperature 
6 months 1 year 
tempe-
rature  
[°C] 
b 
[(mg/L)/month] |b/ub| 
ults, rel 
 
[%] 
tempe-
rature 
°C 
b 
[(mg/L)/month] |b/ub| 
ults, rel 
[%] 
-20 0.002 0.28 0.678 -20 -0.002 0.55 0.733 
4 0.009 1.85 0.491 4 -0.004 1.45 0.591 
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6 Characterisation 
6.1 General principles for the value assignment 
The characterisation of cystatin C in the human serum reference material ERM-DA471/IFCC 
is performed according to the theoretical and practical principles as documented in [12] and 
[16]. The characterisation is achieved by transferring values from the primary reference 
preparation (PRP) to the candidate reference material. The PRP is a solution of the pure 
protein in 0.1 M KCl. It is spiked at different concentrations in a matrix background to 
prepare dilutions that are measured as samples in the measuring system. The dose-
response function of the measuring system is determined by using dilutions of the candidate 
reference material. 
The practical transfer protocol is based on multiple measurements of 6 dilutions of the 
primary reference preparation and 6 dilutions of the candidate reference material under 
repeatability conditions. The transfer protocol requires several measurements a day 
repeated on several days, an important prerequisite being that all reconstitutions and 
dilutions are controlled by weighing, thus reducing uncertainty in the transfer.    
The reference preparation is defined as the protein preparation with known concentration 
value. It can either be an international reference material or a pure protein preparation. For 
this characterisation study a special preparation of pure cystatin C was produced and the 
concentration of cystatin C was obtained using dry mass determination according to [11]. 
Target material is defined as the serum protein matrix material with unknown concentration 
value. In this case it is the new matrix material ERM-DA471/IFCC. 
The transfer method should be based on well established and recognised methods used in 
clinical chemistry. In this characterisation study particle enhanced immuno-turbidimetry, 
particle enhanced immuno-nephelometry and enzyme amplified single radial immuno-
diffusion were used. 
Slight variations in the assay conditions, in the programming of the instruments or in the 
reagents may lead to different results. This has lead to the prerequisite of method 
standardization [17]. To minimise all of these factors contributing to variation, an optimised 
and practical transfer protocol was made with detailed instructions and emphasis on 
weighing all solutions used to prepare dilutions. To record the obtained data, special 
registration forms were made also containing the intended dilution schemes. These raw data 
forms were subsequently sent for data treatment.  
When assigning a value to a target material (a serum) using a pure protein preparation the 
indirect value transfer procedure is used [12]. In this procedure dilutions of the target 
material (TM) are used to determine the dose-response function for the instrument or the 
assay. Dilutions of the primary reference preparation (PRP) are then measured against this 
calibration curve in the following way: 
 
1. 6 different dilutions are prepared of the target material (TM). The concentration of the 
specific protein (although still unknown) in each dilution will be: 
 
  CTM(i)  =  FTM(i) x CTM  (1) 
  
 where FTM is the dilution factor of TM and (i) denotes the different dilutions (i = 1-6). 
 
2. A series of 6 test samples are prepared by adding increasing amounts of the primary 
reference preparation to 6 different test tubes. The final volume of all preparations is then 
adjusted to be the same by adding the dilution solution. The dilutions are made in such a 
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way that the signals will fall within the signal interval of the dose-response curve. The 
concentration of the samples will be: 
 
   CS(j)  =  FPRP(j) x CPRP  (2) 
 
 where FPRP is the dilution factor of PRP and (j) denotes the different dilutions (e.g. j =1-
6). 
 
3. A dose-response function is determined using the dilutions of TM, and by plotting the 
signals against the different dilutions of TM. 
 
4. In a sample run the different dilutions of PRP are measured. The signals of these test 
samples SS(j) are interpolated on the dose-response curve. The resulting concentrations 
CS(j) are now obtained as relative concentrations of TM: 
 
   CS(j)  =  FTM(j) x CTM  (3) 
 
5. Since the unknown concentrations in CS(j) can be either calculated using equation (2) or 
found by interpolation on the dose-response curve (3) a combination of (2) and (3) will 
give: 
 
   CS(j)  = FTM(j) x CTM = FPRP(j) x CPRP 
 
   FTM(j)  = CPRP / CTM  x  FPRP(j)  (4) 
 
 which is the equation of a straight line (y = β x ). 
 
6. The different dilution factors FTM(j) obtained by the interpolation are now plotted against 
the different dilution factors FPRP(j) used for the initial dilution of PRP. Since all dilutions 
are controlled by weighing the uncertainty of FPRP(j) is negligible. 
 If the two materials behave similarly in the method (i.e. there are no matrix effects) the 
regression line will pass through zero with a slope (β) equal to the ratio of the 
concentrations of the specific protein in the two materials: 
 
  β = CPRP / CTM  (5) 
 
 Since the slope can easily be calculated, the unknown concentration CTM is now found to 
be: 
 
 CTM = CPRP / β  (6) 
 
The final characterisation study was conducted using the PRP to assign values to ERM-
DA471/IFCC. The methods including instruments, reagents and laboratories are listed in 
Table 7.  
The practical procedures (the transfer protocols) are based on the following concept, where 
the basic set-up is repeated 3 times each day over 4 days: 
Target material: 6 different dilution levels of the ERM-DA471/IFCC are used as 
standards for the dose-response curve, covering the actual 
measuring interval. 
 
Reference preparation: 6 different dilution levels of the primary reference preparation for 
cystatin C are measured as samples. The dilutions are made in 
such a way that the signals will fall within the signals of the dose-
response curve i.e. within the measuring interval. The samples are 
measured in duplicate. 
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Control:  One selected dilution of the target material is measured in duplicate. 
 
Each of the 4 days (6 days for dataset 2) a new vial of the reference preparation and the 
target material is used and a new set of dilutions is prepared. Each day 3 calibrations are 
performed together with determinations of samples and controls (i.e. 3 runs). 
 
For SRID measurements a slightly modified procedure was developed. Five dilutions of 
target and reference materials were measured in triplicate, in one run per day.  
The transfer procedure was optimised separately for each measuring system participating in 
the value assignment. The dilution scheme was optimised taking into account that dilutions 
automatically carried out by the platforms should be avoided as much as possible (as these 
dilutions cannot be corrected by more accurate weighings). Finally it had to be stressed that 
for each material all 6 dilutions should be prepared from a single vial and that all 
reconstitutions and dilutions are controlled by weighing. 
6.2 Characterisation of the primary reference preparation 
Dry mass determination 
Dry mass determination was started immediately after filling the vials of PRP. It was 
performed according to [11] and documented in [18]. All weighings were carried out on an 
analytical balance. Pyrex glass vials with fitted lids were filled with 3 mL of either protein 
solution or solvent. The sequence of weighing of vials (Empty – Protein Solution – Solvent) 
was repeated four times.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1: Mass of protein solutions and solvents recorded over a period of 7 days 
 
 
Drying was performed in an oven at 90 °C with a slight vacuum of 27 kPa over 7 days. 
Figure 1 shows the mass of the protein solution and the solvent as it was recorded over the 
7 days. 
The mass concentration of cystatin C in the primary reference preparation was then 
calculated according to [11] and found to be: Cp = 5.1971 ± 0.033 g/L, with 
udm, cal, rel = 0.635 %. 
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Physico-chemical characterisation 
The primary reference preparation for cystatin C was further characterised using: 
 
• Agarose screen electrophoresis: cystatin C was migrating at the expected position. 
• SDS-PAGE. These measurements have a limit of detection of 0.5 % (relative mass 
concentration). The results showed that no other protein contaminants could be 
observed when denaturated proteins were separated on the basis of molecular 
weight. As an example an SDS-PAGE is shown in Figure 2. 
• Crossed immunoelectrophoresis: no other serum proteins were detected by poly-
specific antibodies to human serum proteins, cystatin C was detected in the PRP. 
• Double immunodiffusion (Ouchterlony): the precipitation pattern obtained with 
antibodies against cystatin C were consistent with the presence of cystatin C at the 
expected concentration. 
• FPLC Superdex 75 GL and Superdex 200 HR 10/30. These measurements have a 
limit of detection for mass concentrations between 1 and 5 µg/mL, depending on the 
identity of contaminating proteins. No contaminants were found upon the injection of 
cystatin C at a mass concentration of 2 mg/mL (limit of detection for impurities 0.25 
% in relative mass concentration). 
• N-terminal sequencing (Edman and Mass Spectrometry): the protein was identified 
as cystatin C with an intact N-terminus. 
 
 
    kDa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
 
Figure 2: SDS-PAGE of the Primary Reference Preparation for Cystatin C (left) and a molecular  
mass marker (right). Cystatin C has the expected molecular weight, and no impurities can be 
detected in the PRP. 
 
A summary of all characterisations showed that the primary reference preparation for 
cystatin C is monomeric, highly pure, has the expected mobility, has the expected molecular 
mass, and shows high homogeneity. No truncated cystatin C or other non-cystatin C proteins 
were detected. As no impurities could be detected with any of the methods, the purity of the 
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material is 100 % with an estimated relative standard uncertainty of 0.3 %, the value of the 
limit of detection of the size exclusion chromatography measurements rounded up.  
 
This primary preparation was therefore judged qualified to be used in the value assignment 
of the Target Material ERM-DA471/IFCC. 
6.3 Trial run of the characterisation measurements 
In order to test the value assignment procedure and to qualify the different methods and 
laboratories a trial run was conducted using a pure preparation of cystatin C similar to the 
primary reference preparation and with a cystatin C mass concentration of 5.20 g/L, and the 
newly prepared reference material for cystatin C ERM-DA471/IFCC. 
The methods, including instruments, reagents and laboratories, are summarised in Table 6.  
Table 6 Set-up for the trial run 
Principle Instrument Reagent Laboratory 
Single Radial 
Immunodiffusion 
(enzyme amplified) 
 
• Dako 
• Siemens 
L1 
Hitachi 917 • Dako L2 Immuno-turbidimetry 
(Particle enhanced) Hitachi 917 • Roche L3 
Immuno-nephelometry 
(Particle enhanced) BN ProSpec • Siemens L4 
 
A practical protocol was used based on the original principles for an indirect value transfer 
using a carrier matrix for the pure protein. It was found that a solution containing 0.1 mol/L 
KCl and 4 % bovine serum albumin gave the same results as serum when used as a carrier 
matrix. Therefore that solution was used both for pre-dilutions and as a carrier matrix for the 
value assignment. The same solution could be used in all the selected immunochemical 
methods (particle enhanced immuno-turbidimetry and immuno-nephelometry plus enzyme 
amplified single radial immuno-diffusion). 
Based on the obtained data the practical protocol was revised accordingly and final 
registration forms were made. 
All laboratories qualified for the final value assignment. 
6.4 Results of the characterisation measurements 
All four laboratories having participated produced satisfactory results in the trial run and 
participated also in the final characterisation. These laboratories produced a total of 7 
independent datasets.  
The laboratories used the dilutions of the target material to construct the dose-response 
curve directly. The values entered into their instrument for the concentrations of these 
dilutions were the values of the concentrations relative to the concentrations in ERM-
DA471/IFCC, expressed in percent. These relative concentrations were calculated from the 
masses of the solutions. Then for each run, the laboratories measured the dilutions of the 
target material in duplicate.  
Outliers were only rejected if there was a technical reason for doing so (a transcription error, 
wrong dilution, etc.). The different dilution factors FTM(j) obtained by the interpolation were 
plotted against the different dilution factors FPRP(j) used for the initial dilution of PRP.  The 
cystatin C concentration in the target material was calculated from the slope of the linear 
regression line.  
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The following acceptance criteria were applied: 
(1) The mean control value (measured concentration of cystatin C in a control dilution 
of ERM-DA471/IFCC relative to the concentration in the control sample expected on 
the basis of the dilution, calculated from the mass values obtained by weighing) is 
within the interval 1.00 ± 0.05 for turbidimetric and nephelometric methods, and 
within the interval 1.00 ± 0.10 for SRID. 
(2) Tests for linearity (visual inspection and evaluation of the correlation coefficient): 
the correlation coefficient of the linear regression should be higher than 0.98. 
(3) Data from at least 4 dilutions must be available, and the completeness of the data 
must at least be 50 % for each particular day. 
(4) Data from at least two days must be valid. 
In total six measurement days were excluded because mean control values were outside the 
tolerance limit: three from dataset 2, one from dataset 1, and two from dataset 4. For all 
other measurement days valid data were obtained (Figure 3). 
 
Table 7: Summary of the measurements of the cystatin C mass concentrations performed by 
the participating laboratories   
Dataset Laboratory Principle Instrument Reagents cystatin C [mg/L] 
1 L1 SRID - Dako 5.484 
2 L1 SRID - Siemens 5.650 
3 L2 turbidimetry Hitachi 917 Dako 5.526 
4 L3 turbidimetry Hitachi 917 Roche 5.453 
5 L3 turbidimetry Integra 800 Roche 5.518 
6 L4 nephelometry BN ProSpec Siemens 5.313 
7 L4 nephelometry BNII Siemens 5.391 
Mean of means 5.477 
RSD [%] 1.96 
 
The individual daily measured values and the laboratory means are normally distributed at 
α = 0.05 (error probability upon rejection of the zero hypothesis). There were no outlying 
laboratory means according to Dixon’s, Nalimovs t-test, and Grubbs test.  
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Figure 3: Results of the characterisation measurements of the mass concentration of cystatin 
C. The bars represent the dataset means ± s. The dotted line represents the mean of means, 
and the bars at the beginning and the end of the dotted line represents the mean of means ± s. 
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7 Uncertainty budget and certified value 
7.1 Estimation of the uncertainty 
The uncertainty components consist of the relative standard uncertainty related to 
characterisation (uchar, rel), the relative standard uncertainty of the dry mass determination and 
the purity of the PRP (udm, cal, rel and upurity, cal, rel), and the uncertainties due to the between-
bottle heterogeneity (ubb, rel), and possible degradation during long-term storage (ults, rel) [19]. 
• uchar, rel was estimated as the relative standard uncertainty of the mean of 
laboratory means, i.e. s/(p)0.5 with s the relative standard deviation of the mean of 
laboratory means and p the number of datasets, converted into a relative value 
• udm, cal, rel was taken as the relative standard uncertainty of the dry mass 
determination 
• upurity, cal, rel was estimated from the uncertainty of the purity assessment of the PRP 
by size exclusion chromatography 
• ubb, rel was taken as the sbb, rel as defined in Section 4.1.  
• ults, rel was estimated from stability tests and were taken from Table 5 (12 month 
stability study). 
The relative combined standard uncertainty was calculated as the square root of the sum of 
squares of the individual contributions, according to: 
2
rel lts,
2
rel bb,
2
rel  cal, purity,
2
rel cal, dm,
2
rel char,rel c, uuuuuu ++++=   
The various uncertainty contributions and the relative combined standard uncertainty (uc, rel) 
are shown in Table 8. 
 
Table 8: Uncertainty budget for ERM-DA471/IFCC 
uchar, rel 
[%] 
Udm, cal, rel 
[%] 
upurity, cal, rel 
[%] 
ubb, rel 
[%] 
ults, rel 
[%] 
uc, rel 
[%] 
0.74 0.64 0.3 0.29 0.73 1.29 
7.2 Certified values 
The certified value (Table 9) was taken as the mean of means of the laboratory results 
(Table 7). 
The relative expanded uncertainty was calculated from the relative combined standard 
uncertainty uc, rel (Table 8) by multiplication with a coverage factor k. This coverage factor 
was taken as 2, corresponding to a level of confidence of approximately 95 %. The relative 
expanded uncertainty was multiplied with the mean of dataset means to obtain the expanded 
uncertainty UCRM.  
 
Table 9: Certified value and expanded uncertainty for the mass concentration of cystatin C in 
ERM-DA471/IFCC 
Certified value 
[mg/L] 
UCRM (k = 2) 
[mg/L] 
5.48 0.15 
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8 Metrological traceability 
The certified values for cystatin C in ERM-DA471/IFCC was assigned by transferring values 
from a pure protein reference preparation applying the value transfer procedure as described 
in the report. The value transfer measurements were strictly controlled with respect to the 
adherence to the procedure and the adequate functioning of equipment and reagents was 
verified. The methods used were all immunochemical ones. Different combinations of 
reagents and measuring systems were used, and gave consistent results. Therefore the 
results are not dependent on the individual measurement procedures. 
The concentration of cystatin C in the pure protein reference preparation had been assigned 
using a procedure based entirely on weighings, and is traceable to the SI. 
Therefore the value of cystatin C in ERM-DA471/IFCC is traceable to the pure protein 
reference preparation, and thus to the SI, applying the procedures described in the present 
report.  
9 Commutability 
If ERM-DA471/IFCC is used for the calibration of other cystatin C assays it should be verified 
by the user that the material or its dilution used is commutable for that particular method in 
combination with other methods.  
ERM-DA471/IFCC and its dilutions prepared using the assay diluent have been shown to be 
commutable for combinations of the Siemens N Latex Cystatin C Test Kit run on a BN 
ProSpec, the Sentinel CH assay run on an Architect c16000,  and the Gentian cystatin C 
immunoassay run on an Architect. Dilutions with a mass fraction of ERM-DA471/IFCC in the 
dilution buffer of the relevant assay kit equal to or below 0.6 are commutable for 
combinations of these three assays and the Roche tina quant cystatin C assay run on a 
Cobas c501.
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10 Intended use and instructions for use 
The material is primarily intended to be used for the calibration of immunoassay-based IVD 
products for the measurement of cystatin C.  
When the material is used as a calibrant in a particular assay the commutability should be 
verified for the assay concerned.  
The entire content of the vial must be reconstituted. The minimum sample intake for which 
the material was shown to be homogenous was 2 µL. 
 
Reconstitution of the material 
To make it ready for use, the material has to be reconstituted according to the following 
procedure: 
• Remove the vial from the freezer during the afternoon of the day before use and place 
the vial for 1 hour in the room where the balance is located. 
• After one hour, tap the bottom of the vial gently on the surface of the table. Make sure 
that all the material has settled down on the bottom of the vial. Remove the screw cap. 
• Weigh the vial together with the rubber stopper. Document the mass or press the “TARE” 
button on the balance. Lift the rubber stopper with care until air is allowed to enter the 
vial and the groove in the rubber stopper becomes accessible. 
• Add 1.00 mL of water through the groove, and press the rubber stopper back into place. 
Weigh the vial and document the mass. If you have used the “TARE” function, the value 
can be used directly for the mass m. Otherwise the first mass value must be subtracted 
from the second to obtain m. 
• The concentration of cystatin C in the solution can be calculated using the actual 
reconstitution mass m and the intended reconstitution mass (1.000 g).  
• Leave the vial at room temperature for one hour, then invert it carefully at least five times 
(do not shake it) during the next hour. 
• Leave the vial at room temperature overnight. On the day of use invert the vial carefully 
five times. 
 
Storage 
Unopened ampoules should be stored at or below -20 °C. Under the condition that any 
microbial contamination during the reconstitution procedure has been excluded, the solution 
of ERM-DA471/IFCC can be used for one week, as it was verified that changes in the 
certified concentration observed during that period are not significant. It is advisable to cover 
the vial with the original seal after use and to store it at 2 - 8 °C.  
However, the European Commission cannot be held responsible for changes that happen 
during storage of the material at the customer's premises, especially of opened samples. 
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The certified cystatin C mass concentration in ERM-DA471/IFCC, if reconstituted according to the 
specified procedure, is 5.48 mg/L, the expanded uncertainty (k = 2) is 0.15 mg/L. 
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